Igor Popa

TL;DR: There was a significant positive correlation of the inhibitory effects on human and plant CDKs with cell proliferation of cancer and cytokinin-dependent tobacco cells, respectively, which suggests that at least a part of the antiproliferative effect of the new cytokinins was due to the inhibition of CDK activity.

TL;DR: Cytokinin activity of forty-eight 6-benzyladenosine derivatives at both the receptor and cellular levels as well as their anticancer properties were compared in various in vitro assays, suggesting that it may be possible to modulate particular cytokinin-dependent processes with specific compounds.

TL;DR: The susceptibility of several new derivatives to enzyme degradation by cytokinin oxidase/dehydrogenase was studied and the cytotoxicity of the prepared compounds against human diploid fibroblasts and the human cancer cell lines K-562 and MCF-7 was also assayed in vitro.

TL;DR: The identification of the first known molecule antagonizing the activity of the plant hormone cytokinin at the receptor level, designated PI‐55, which represents an initial step for the preparation of cytokinIn antagonists with broad activity and reduced agonistic properties is reported.

TL;DR: The synthesis and in vitro biological testing of eleven BAP derivatives substituted in the benzyl ring and in the C2, N7 and N9 positions of the purine moiety identified 6-(2,5-Dihydroxybenzylamino)purine (LGR-991) was identified as a cytokinin receptor antagonist and exhibits a structural motive that might lead to preparation of cytokinIn antagonists with a broader specificity and reduced agonistic properties.